• Font Size

About Us

Boston Biomedical is focused on the research and development of novel cancer therapeutics, and has developed a world-leading product pipeline targeting cancer stem cells.

Product Pipeline

BBI608 is the most clinically advanced candidate in Boston Biomedical’s cancer stem cell (CSC) pathway inhibitor program. This first-in-class, orally-administered small molecule blocks CSC self-renewal and induces cell death in CSCs as well as non-stem cancer cells.

Tell me more